Brief: Immunocore Holdings Says Early On-Treatment ctDNA Reduction In Stable Disease Patients Treated With KIMMTRAK Was Associated With Longer Overall Survival
03/06/2023 12:06
June 3 (Reuters) - Immunocore Holdings PLC IMCR.O :
* IMMUNOCORE PRESENTS ADDITIONAL CTDNA DATA FROM THE
KIMMTRAK
PHASE 3 TRIAL AT ASCO
* IMMUNOCORE HOLDINGS -EARLY ON-TREATMENT CTDNA REDUCTION IN
STABLE DISEASE PATIENTS TREATED WITH KIMMTRAK WAS ASSOCIATED
WITH LONGER OVERALL SURVIVAL
Source text for Eikon: ID:nGNE1PTbgD
Further company coverage: IMCR.O
((Reuters.Briefs@thomsonreuters.com;))